{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:45:10Z","timestamp":1791726310240,"version":"4.3.4"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>\n            Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and\n            <jats:italic>in vitro<\/jats:italic>\n            activity are important efficacy indicators, but accepted susceptibility methods do not always accurately predict activity in an acidic environment, such as the vagina.\n          <\/jats:p>","DOI":"10.1128\/aac.02611-18","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T10:39:35Z","timestamp":1552473575000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["A Novel 1,3-Beta-\n            <scp>d<\/scp>\n            -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis"],"prefix":"10.1128","volume":"63","author":[{"given":"E. L.","family":"Larkin","sequence":"first","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Long","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Isham","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barat","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wring","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200605000-00049"},{"key":"e_1_3_2_3_2","first-page":"36","volume-title":"ACOG clinical updates in women\u2019s health care","author":"American College of Obstetricians and Gynecologists","year":"2009","unstructured":"American College of Obstetricians and Gynecologists. 2009. Vulvar disorders. ACOG clinical updates in women\u2019s health care, vol 8, no. 2, p 36. American College of Obstetricians and Gynecologists, Washington, DC."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60917-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363110-00002"},{"key":"e_1_3_2_6_2","volume-title":"CLSI document M27-A4","author":"Clinical and Laboratory Standards Iinstitute","year":"2018","unstructured":"Clinical and Laboratory Standards Iinstitute. 2018. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard\u20143rd ed. CLSI document M27-A4. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.07.010"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1383"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01961-16"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00244-18"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.06.067"},{"key":"e_1_3_2_12_2","volume-title":"Diflucan package insert","author":"Pfizer, Inc","year":"2011","unstructured":"Pfizer, Inc. 2011. Diflucan package insert. Pfizer, Inc. New York, NY."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733010-00005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(02)00233-6"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05025-11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000383"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx422"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02611-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02611-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:28:13Z","timestamp":1645478893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02611-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1128\/AAC.02611-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02611-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"2018-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02611-18"}}